Pfizer Hasn't Proved Rare-Disease Drug Works, FDA Staff Says
The agency’s feedback came in advance of a Thursday advisory committee meeting where a panel of outside experts will vote on whether the medicine should be cleared for sale.
Dr. Devanand Jillapalli, who analyzed clinical trial results submitted by Pfizer, concluded that there is “inadequate evidence of...
Already a subscriber? Click here to login